Hightide Therapeutics Inc (2511) AI Stock Analysis

• Market Cap: HK$1.48B
• Dividend Yield: N/A
• Average Volume (3M): 3.83M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.37
• Revenue Growth: N/A
• EPS Growth: 54.79%
• Country: HK
• Employees: 70
• Sector: General
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): -0.92
• Shares Outstanding: 514,770,700
• 10 Day Avg. Volume: 4,568,890
• 30 Day Avg. Volume: 3,828,846
• PEG Ratio: 0.00
• Price to Book (P/B): -19.10
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -57.59
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 36 Underperform
• Price Target: ―

Hightide Therapeutics Inc's stock score is primarily affected by its financial instability due to the absence of revenue, leading to poor profitability and cash flow scores. While the technical analysis suggests positive momentum, the overall financial health and valuation concerns limit the stock's appeal. Without earnings, the valuation remains unattractive, despite some technical strength.

Hightide Therapeutics Inc Business Overview & Revenue Model

Company Description

Hightide Therapeutics Inc (2511) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of metabolic and digestive diseases. The company leverages its expertise in drug development to address unmet medical needs and improve patient outcomes. Hightide Therapeutics is committed to advancing its pipeline of proprietary compounds and fostering collaborations to bring novel treatments to market.

How the Company Makes Money

Hightide Therapeutics Inc generates revenue through the development and commercialization of its proprietary drug candidates. The company earns money by advancing its product pipeline through clinical trials and securing regulatory approvals for its therapies. Revenue streams include potential partnerships and licensing agreements with other pharmaceutical companies, which can provide milestone payments and royalties. Additionally, Hightide may receive funding through collaborations with research institutions and government grants aimed at supporting innovative healthcare solutions. These partnerships and collaborations are significant contributors to the company's earnings, allowing it to fund ongoing research and development activities.

Hightide Therapeutics Inc Financial Statement Overview

Summary

Hightide Therapeutics Inc faces significant financial challenges typical for early-stage biotechnology firms. The lack of revenue impacts profitability and cash flow negatively, while a strong cash position provides some buffer. Continued reliance on external financing highlights the need for successful product development and commercialization to improve financial health.

Income Statement

Hightide Therapeutics Inc is currently not generating any revenue, which is a significant challenge as it affects profitability metrics. The company is experiencing substantial losses, reflected in negative EBIT and Net Income. Without revenue, profitability margins cannot be calculated, underscoring the company's current financial instability.

Balance Sheet

The balance sheet shows a relatively healthy cash position with cash and short-term investments significantly higher than total debt, resulting in negative net debt, which is a positive indicator of liquidity. However, the company has had negative stockholders' equity in previous years, indicating potential financial distress. The improvement in equity position in the latest year is a positive sign but needs to be sustained.

Cash Flow

Cash flow analysis reveals consistent negative operating cash flow, highlighting ongoing cash burn without revenue generation. The absence of free cash flow growth and reliance on financing activities for cash inflows presents a risk. While the company has managed to maintain cash reserves, the cash flow situation remains precarious without incoming revenue.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement		Total Revenue
0.00	0.00	0.00	0.00
	Gross Profit
0.00	―	―	―
	EBIT
-444.75K	-440.36M	-230.86M	-129.89M
	EBITDA
-444.22K	-959.43M	-229.56M	-128.33M
	Net Income Common Stockholders
-381.79K	-939.31M	-194.25M	-217.49M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
490.52M	735.70M	828.33M	763.91M
	Total Assets
559.93M	795.04M	843.73M	777.23M
	Total Debt
77.91M	16.43M	1.25B	1.01B
	Net Debt
-232.84M	-591.78M	846.32M	248.32M
	Total Liabilities
135.76M	92.26M	1.30B	1.03B
	Stockholders Equity
424.17M	702.77M	-463.88M	-271.77M
Cash Flow		Free Cash Flow
-302.75M	-358.72M	-172.90M	-90.12M
	Operating Cash Flow
-298.47M	-357.92M	-172.71M	-88.40M
	Investing Cash Flow
-54.66M	316.66M	-428.06M	―
	Financing Cash Flow
0.00	361.10M	47.32M	486.12M

Hightide Therapeutics Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.88
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2511, the sentiment is Positive. The current price of 2.88 is above the 20-day moving average (MA) of 2.69, above the 50-day MA of 2.39, and above the 200-day MA of 1.47, indicating a bullish trend. The MACD of 0.18 indicates Negative momentum. The RSI at 53.22 is Neutral, neither overbought nor oversold. The STOCH value of 33.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2511.

Hightide Therapeutics Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1093	76 Outperform	$87.63B	19.06	13.20%	2.62%	-9.60%	-27.18%
2269	74 Outperform	$98.06B	27.18	8.17%	―	7.52%	-1.92%
1177	66 Neutral	$89.24B	47.03	6.14%	12.58%	7.63%	-24.23%
2196	65 Neutral	$65.06B	13.78	6.22%	1.93%	-2.82%	11.93%
1873	58 Neutral	HK$3.28B	18.36	4.47%	―	-9.75%	―
Sector *	57 Neutral	HK$23.47B	12.09	-15.60%	18.90%	10.12%	-85.27%
2511	36 Underperform	HK$1.48B	―	-67.57%	―	―	54.79%

Hightide Therapeutics Inc Corporate Events

HighTide Therapeutics’ HTD1801 Shows Promising Results in Phase 3 Trials for Type 2 Diabetes

HighTide Therapeutics announced that their lead compound, HTD1801, met the primary endpoints in two Phase 3 clinical trials for patients with type 2 diabetes mellitus. The trials, named SYMPHONY 1 and SYMPHONY 2, demonstrated significant glucose-lowering effects and improvements in cardiometabolic risk indicators. Based on these results, HighTide plans to submit a new drug application for HTD1801 in China. The trials also showed favorable safety and tolerability profiles, with minimal adverse events reported.

HighTide Therapeutics Reports Promising 2024 Results with Core Product HTD1801

HighTide Therapeutics announced its audited consolidated annual results for 2024, highlighting the potential of its core product, HTD1801, in treating chronic metabolic diseases. HTD1801, a gut-liver anti-inflammatory metabolic modulator, has shown promising clinical proof of concept data, demonstrating a broad range of cardiometabolic benefits such as improved glycemic control, weight reduction, and lipid-lowering effects. The product’s dual mechanism of action, involving AMPK activation and NLRP3 inflammasome inhibition, positions it as a unique broad-spectrum metabolic regulator. This development could significantly impact the company’s operations and industry positioning by addressing patient needs more effectively.

HighTide Therapeutics Schedules Board Meeting for Annual Results Approval

HighTide Therapeutics, Inc. has announced a board meeting scheduled for March 28, 2025, to discuss and approve the audited annual results for the year ending December 31, 2024. This meeting is crucial for stakeholders as it will provide insights into the company’s financial performance and future strategies.